There was no significant harm or benefit associated with repeat testing in women with an initial normal result; 30% to 40% of these women changed the PlGF-based test category on repeat tests and 20% developed preeclampsia, with a higher proportion in symptomatic women. The gene discussed is PGF; the disease is preeclampsia.